Search Results - "Kaveri, S V"

Intravenous immunoglobulins - understanding properties and mechanisms by Durandy, A, Kaveri, S.V, Kuijpers, T.W, Basta, M, Miescher, S, Ravetch, J.V, Rieben, R

“…High-dose intravenous immunoglobulin (IVIg) preparations are used currently for the treatment of autoimmune or inflammatory diseases. Despite numerous studies…”
Get full text

Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy by Kaveri, S. V., Maddur, M. S., Hegde, P., Lacroix‐Desmazes, S., Bayry, J.

“…Summary Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more…”
Get full text

Natural Immunomodulators by Ortuño-Sahagún, D., Zänker, K., Rawat, A. K. S., Kaveri, S. V., Hegde, P.

“…The relevance of this research would be crucial to the search for better treatments, both to complement those that already exist and to develop new strategies…”
Get full text

Atheroprotective effect of adjuvants in apolipoprotein E knockout mice by Khallou-Laschet, J., Tupin, E., Caligiuri, G., Poirier, B., Thieblemont, N., Gaston, A.-T., Vandaele, M., Bleton, J., Tchapla, A., Kaveri, S.V., Rudling, M., Nicoletti, A.

“…Strategies aimed at treating atherosclerosis by immunization protocols are emerging. Such protocols commonly use adjuvants as non-specific stimulators of…”
Get full text

Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors by Grosbois, S. S., Brionne, M. F., de Longcamp, A. L. F., Gautier, P., V Kaveri, S., Borel-Derlon, A., Repessé, Y.

“…Summary The major complication of the substitutive treatment of haemophilia A (HA) is the development of antifactor VIII (FVIII) antibodies. Most of these…”
Get full text

Mechanisms of action of intravenous immune globulin in immune‐mediated diseases by Mouthon, L., Kaveri, S. V., Spalter, S. H., Lacroix-Desmazes, S., Lefranc, C., Desai, R., Kazatchkine, M. D.

“…Intravenous immune globulin (IVIG) exhibits a number of immunomodulatory properties that are mediated by the Fe portion of IgG and by the spectrum of variable…”
Get full text

Self-reactive antibodies (natural autoantibodies) in healthy individuals by Lacroix-Desmazes, Sébastien, Kaveri, Srini V, Mouthon, Luc, Ayouba, Ahidjo, Malanchère, Evelyne, Coutinho, Antonio, Kazatchkine, Michel D

“…Antibodies that are present in the serum of healthy individuals in the absence of deliberate immunization with any antigen, are refered to as natural…”
Get full text

Association of clinical presentation with anti-nuclear antibody specificities among patients with systemic lupus erythematosus by Pradhan, V, Patwardhan, M, Rajadhyksha, A, Umare, V, Khadilkar, P, Kaveri, S V, Ghosh, K

Get full text

Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases by KAVERI, S.‐V., DIETRICH, G., HUREZ, V., KAZATCHKINE, M. D

“…SUMMARY Intravenous immunoglobulin (IVIg) therapy is increasingly used in autoimmune diseases. Although its efficacy has only been established in a few…”
Get full text

Role of the Intrinsic Coagulation Pathway in Atherogenesis Assessed in Hemophilic Apolipoprotein E Knockout Mice by Khallou-Laschet, J, Caligiuri, G, Tupin, E, Gaston, A -T, Poirier, B, Groyer, E, Urbain, D, Maisnier-Patin, S, Sarkar, R, Kaveri, S V, Lacroix-Desmazes, S, Nicoletti, A

“…OBJECTIVE—The contribution of thrombosis and coagulation in atherogenesis is largely unknown. We investigated the contribution of the coagulation intrinsic…”
Get full text

Natural Autoantibodies as Tools to Predict the Outcome of Immune Response? by Kohler, H., Bayry, J., Nicoletti, A., Kaveri, S. V.

“…Natural autoantibodies (NAbs), produced by B‐1 B‐cells, are directed against autoantigens and pathogens. NAbs can capture and present antigen to T helper cells…”
Get full text

Intravenous immunoglobulin and immune response by Kaveri, S. V., Lecerf, M., Saha, C., Kazatchkine, M. D., Lacroix‐Desmazes, S., Bayry, J.

Get full text

Mechanisms of action of intravenous immunoglobulins in autoimmune and inflammatory diseases by BAYRY, J, MISRA, N, LATRY, V, PROST, F, DELIGNAT, S, LACROIX-DESMAZES, S, KAZATCHKINE, KAVERI, S. V

Get full text

Expression and control of the natural autoreactive IgG repertoire in normal human serum by Hurez, V, Kaveri, S V, Kazatchkine, M D

“…We have investigated the autoreactive repertoire expressed by serum IgG of healthy individuals of various age groups using a large panel of self antigens…”
Get more information

Antibodies to C-C Chemokine Receptor 5 in Normal Human IgG Block Infection of Macrophages and Lymphocytes with Primary R5-Tropic Strains of HIV-1 by Bouhlal, Hicham, Hocini, Hakim, Quillent-Gregoire, Caroline, Donkova, Vladimira, Rose, Stephanie, Amara, Ali, Longhi, Renato, Haeffner-Cavaillon, Nicole, Beretta, Alberto, Kaveri, Srini V, Kazatchkine, Michel D

“…In the present study, we demonstrate that normal human IgG for therapeutic use (i.v. Ig) contains natural Abs directed against the CCR5 coreceptor for HIV-1…”
Get full text

Role of coagulation‐associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A by Gangadharan, B., Delignat, S., Ollivier, V., Gupta, N., Mackman, N., Kaveri, S. V., Lacroix‐Desmazes, S.

“…Summary Background Immune responses to therapeutic factor VIII remain a major problem, affecting 30% of patients with severe hemophilia A. The primary factors…”
Get full text

Invariance and Restriction Toward a Limited Set of Self-Antigens Characterize Neonatal IgM Antibody Repertoires and Prevail in Autoreactive Repertoires of Healthy Adults by Mouthon, Luc, Nobrega, Alberto, Nicolas, Nathalie, Kaveri, Srinivas V., Barreau, Claude, Coutinho, Antonio, Kazatchkine, Michel D.

“…Analysis of the reactivity of IgM with self-antigens in tissues by a quantitative immunoblotting technique showed striking invariance among newborns in the…”
Get full text

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A by DELIGNAT, S., REPESSÉ, Y., NAVARRETE, A. -M., MESLIER, Y., GUPTA, N., CHRISTOPHE, O. D., KAVERI, S. V., LACROIX-DESMAZES, S.

“…The development of inhibitory anti‐factor VIII (FVIII) antibodies in patients with haemophilia A following replacement therapy is associated with several types…”
Get full text

Splenic marginal zone antigen‐presenting cells are critical for the primary allo‐immune response to therapeutic factor VIII in hemophilia A by NAVARRETE, A., DASGUPTA, S., DELIGNAT, S., CALIGIURI, G., CHRISTOPHE, O. D., BAYRY, J., NICOLETTI, A., KAVERI, S. V., LACROIX‐DESMAZES, S.

“…Background: Alloimmune responses to intravenously administered protein therapeutics are the most common cause of failure of replacement therapy in patients…”
Get full text

Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice by Peyron, I., Dimitrov, J. D., Delignat, S., Gangadharan, B., Planchais, C., Kaveri, S. V., Lacroix-Desmazes, S.

Get full text